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Anti-coagulation therapy for stroke 
prevention in Atrial Fibrillation (AF) has 
been dominated by the drug warfarin for 
more than 50 years, yet three recently 
approved drugs are viable therapeutic 
alternatives to warfarin. However, 
according to Dr. Jackson, Program 
Director for Applied Health Economics 
and Outcomes Research at JSPH, they 
are not without challenges to optimize 
care for AF patients. He helped provide 
a clear and insightful overview of this 
topic at a recent Forum. Dr. Jackson 
has over 30 years of experience in the 
pharmaceutical industry, with much of 
this time devoted to clinical research 
and the management and practice of 
Outcomes Research, including the 
transition of clinical evidence into user-
friendly cost-effectiveness models. 
The framework for Dr. Jackson’s 
presentation was based on outcomes 
research, which he described as the 
“study that studies the studies.” The 
purpose of outcomes research, according 
to the Agency for Healthcare Research 
and Quality (AHRQ), is to examine three 
questions: 1) Do patients benefit? 2) 
What treatments work best? And, 3) Are 
health-care resources well spent? 
Jackson first cited the incidence of AF 
by explaining that approximately 15% of 
all strokes occur in people with AF; the 
risk of stroke in patients with untreated 
AF averages 5% per year and increases 
with advancing age. Jackson emphasized 
the chronic and devastating nature of AF 
and the importance of understanding the 
efficacy and the effectiveness in the real 
world of therapeutic options. 
For many years, warfarin has been the 
only oral anti-coagulant available for 
chronic care. Though hugely successful 
in terms of stroke prevention, its 
use presents numerous challenges in 
everyday practice, particularly for 
chronically ill, elderly patients. For 
example, warfarin is known to have 
many interactions with other drugs and 
foods, and requires constant monitoring. 
There is a narrow therapeutic range, 
and the blood test monitoring of the 
INR (International Normalized Ratio), 
can be a significant barrier for certain 
populations as well as caregivers. Most 
significant is that warfarin is a leading 
cause of adverse drug events and 
associated visits to emergency rooms, 
Jackson explained. 
A new group of anti-coagulants, called 
“Novel Oral Anticoagulants” or NOAC, 
including dabigatran, rivaroxiban, and 
apixaban, open the door for promising 
alternatives to warfarin, with fewer 
complexities in the treatment regimens. 
Dr. Jackson offered an overview of 
the major clinical studies, and even 
indirectly compared some of the findings, 
after warning the audience about the 
dangers of indirect comparisons. 
Relating this back to outcomes research, 
Jackson tackled the questions, “what 
treatment works best?” and “are 
healthcare resources well spent?” 
NOACs, he explained, are unique 
compared to warfarin in that they 
don’t need INR monitoring, but as 
anti-coagulants they still need careful 
oversight. In many key outcomes, 
NOACs were actually superior or better 
than warfarin; however, until real-world 
safety and effectiveness are confirmed, 
their promise of a superior alternative to 
warfarin remains to be seen. He closed 
by affirming that most effective therapies 
prove cost-effective, and for the NOACs 
real-world scenarios will be crucial to 
assess their ultimate value. 
Throughout his presentation, Dr. Jackson 
acknowledged the work and expertise 
of Geno J. Merli, MD, Co-Director of 
the Vascular Center at Jefferson, and a 
national expert on anticoagulant therapy. 
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